Okayama University

Gunma University

Niigata University

Momotaro-Gene Inc.

Rie Kinoshita

Junichiro Futami

Hiromi Kumon

Masakiyo Sakaguchi

Eisaku Kondo

Hiroki Sato

Kazuhiko Shien

Shuta Tomida

Shinichi Toyooka

Mikio Okazaki

Yusuke Inoue

Kota Araki

Akira Yamauchi

Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

Anti-S100A8/A9 antibody and use thereof

This invention provides an anti-REIC antibody that specifically recognizes a cancer-associated protein (REIC/Dkk-3) and enables monitoring of cancer treatment effects involving the use of the REIC/Dkk-3 gene or the REIC/Dkk-3 protein as a medicine. This invention also provides a method of diagnosis involving the use of such antibody. The method of diagnosis comprises a method of cancer detection comprising: measuring the REIC/Dkk-3 protein concentration in the biological sample obtained from a subject with the use of a first antibody or a functional fragment thereof that specifically recognizes the REIC/Dkk-3 protein having an active structure produced by a normal cell but does not recognize and bind to the REIC/Dkk-3 protein existing at a high level in the blood from a cancer patient or has low reactivity with the REIC/Dkk-3 protein existing at a high level in the blood from a cancer patient; and, when the REIC/Dkk-3 protein concentration in the biological sample obtained from the subject is lower than the REIC/Dkk-3 protein concentration in the biological sample from a healthy individual, determining that the subject is suffered from precancer or a neoplastic disease.

Antibody that specifically recognizes and binds to REIC/Dkk-3 protein having active structure and monitoring of cancer treatment using such anti-REIC/Dkk-3 antibody

Growing community of inventors

Okayama, Japan

Rie Kinoshita